3 Results for "

glucolipotoxicity

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "glucolipotoxicity" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-19618
CAS No.: 1550053-02-5
Target:  

HDAC HIV Apoptosis

Research Areas:  

Infection Metabolic Disease

BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .
loading...
    loading...
Cat. No.: HY-170593
CAS No.: 3067202-14-3
Target:  

Molecular Glues

Research Areas:  

Metabolic Disease

ChREBPα/14-3-3 regulator-1 (Compound 43) is a selective molecular gel that can stabilize the interaction of carbohydrate response element binding protein (ChREBP) with 14-3-3 proteins (EC50: 3.8 μM). ChREBPα/14-3-3 regulator-1 effectively protects β cells from glucolipotoxicity and maintains cell function, and can be used in the study of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-183871
CAS No.: 1253197-38-4
WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain .
loading...
    loading...